Skip to main content

Advertisement

SpringerLink
Log in

Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder

  • Letter to the Editor
  • Published:
World Journal of Urology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability statement

Not applicable.

References

  1. Szabados B, Kockx M, Assaf ZJ et al (2022) Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol 82:212–222. https://doi.org/10.1016/j.eururo.2022.04.013

    Article  CAS  PubMed  Google Scholar 

  2. Kamoun A, de Reyniès A, Allory Y et al (2020) A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol 77:420–433. https://doi.org/10.1016/j.eururo.2019.09.006

    Article  PubMed  Google Scholar 

  3. Robertson AG, Kim J, Al-Ahmadie H et al (2017) Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171:540–556. https://doi.org/10.1016/j.cell.2017.09.007

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Abrahamsson J, Aaltonen K, Engilbertsson H et al (2017) Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: association with tumor stage, lymph node metastases, fdg-pet findings, and survival. Urol Oncol 35:606–609. https://doi.org/10.1016/j.urolonc.2017.05.021

    Article  CAS  Google Scholar 

  5. Rink M, Schwarzenbach H, Riethdorf S et al (2019) The current role and future directions of circulating tumor cells and circulating tumor dna in urothelial carcinoma of the bladder. World J Urol 37:1785–1799. https://doi.org/10.1007/s00345-018-2543-9

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was supported by National Key Research and Development Program of China (2018YFA0902802).

Author information

Authors and Affiliations

  1. Department of Urology, Peking University People’s Hospital, Beijing, 100044, China

    Yuxuan Song & Tao Xu

Authors
  1. Yuxuan Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tao Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YS: project development, literature collection and manuscript writing. TX: project development and manuscript writing.

Corresponding author

Correspondence to Tao Xu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Not applicable.

Informed consent

All the authors consent for the publication of the article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Song, Y., Xu, T. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. World J Urol 41, 1697–1698 (2023). https://doi.org/10.1007/s00345-023-04430-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-023-04430-y

Search

Navigation